PT3088353T - Partículas de bilirrubina e sua preparação para utilização em terapia - Google Patents
Partículas de bilirrubina e sua preparação para utilização em terapiaInfo
- Publication number
- PT3088353T PT3088353T PT148753494T PT14875349T PT3088353T PT 3088353 T PT3088353 T PT 3088353T PT 148753494 T PT148753494 T PT 148753494T PT 14875349 T PT14875349 T PT 14875349T PT 3088353 T PT3088353 T PT 3088353T
- Authority
- PT
- Portugal
- Prior art keywords
- preparation
- method therefor
- bilirubin nanoparticle
- bilirubin
- nanoparticle
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130165718 | 2013-12-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3088353T true PT3088353T (pt) | 2020-02-24 |
Family
ID=53479252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT148753494T PT3088353T (pt) | 2013-12-27 | 2014-12-26 | Partículas de bilirrubina e sua preparação para utilização em terapia |
Country Status (10)
Country | Link |
---|---|
US (2) | US11904019B2 (pt) |
EP (1) | EP3088353B8 (pt) |
KR (1) | KR101681299B1 (pt) |
DK (1) | DK3088353T3 (pt) |
ES (1) | ES2774035T3 (pt) |
HR (1) | HRP20200256T1 (pt) |
HU (1) | HUE047912T2 (pt) |
PL (1) | PL3088353T3 (pt) |
PT (1) | PT3088353T (pt) |
WO (1) | WO2015099492A1 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102254093B1 (ko) * | 2017-05-12 | 2021-05-20 | 주식회사 빌릭스 | 빌리루빈 유도체 및 금속을 포함하는 입자 |
KR102056948B1 (ko) * | 2018-02-05 | 2019-12-17 | 주식회사 빌릭스 | 빌리루빈 유도체 기반의 진단 및 치료용 초음파 조영제 |
CN110898228B (zh) * | 2018-09-17 | 2022-10-04 | 天津大学 | 肿瘤自靶向光致异构纳米载体及其制备方法 |
WO2020154110A1 (en) * | 2019-01-22 | 2020-07-30 | Purdue Research Foundation | Bilirubin-coated radio-luminescent particles |
WO2020176289A1 (en) * | 2019-02-25 | 2020-09-03 | The University Of Toledo | Pegylated bilirubin for the treatment of hyperlipidemia, obesity, fatty liver disease cardiovascular diseases and type ii diabetes |
CN112618730A (zh) * | 2019-09-24 | 2021-04-09 | 天津大学 | 一种活性氧响应性纳米药物-基因共递送体系及其制备方法 |
CN112023060B (zh) * | 2020-09-16 | 2023-06-13 | 上海市第一人民医院 | 一种靶向软骨具光热响应特征的双药负载纳米微球及其制备方法和应用 |
KR102591787B1 (ko) * | 2021-01-13 | 2023-10-20 | 한국과학기술원 | 키토산-빌리루빈 접합체를 포함하는 입자 및 이를 포함하는 약제학적 조성물 |
CN112972392B (zh) * | 2021-03-10 | 2022-06-21 | 温州医科大学附属第二医院(温州医科大学附属育英儿童医院) | 一种胆红素纳米颗粒及其制备和应用 |
CN115317437B (zh) * | 2021-05-11 | 2023-09-08 | 中国科学院上海硅酸盐研究所 | 一种基于胆红素纳米材料的胰岛素递送微针及其制备方法 |
WO2023018217A1 (ko) | 2021-08-11 | 2023-02-16 | 주식회사 빌릭스 | 빌리루빈의 합성 방법 |
WO2023018215A1 (ko) | 2021-08-11 | 2023-02-16 | 주식회사 빌릭스 | 빌리루빈의 합성 방법 |
WO2023018214A1 (ko) | 2021-08-11 | 2023-02-16 | 주식회사 빌릭스 | 빌리루빈의 합성 방법 |
CN117813301A (zh) | 2021-08-11 | 2024-04-02 | 株式会社毕丽斯 | 胆红素的合成方法 |
CN117881673A (zh) | 2021-08-11 | 2024-04-12 | 株式会社毕丽斯 | 胆红素的合成方法 |
KR102553482B1 (ko) | 2021-08-11 | 2023-07-10 | 주식회사 빌릭스 | 빌리루빈의 합성 방법 |
CN114767839A (zh) * | 2021-10-28 | 2022-07-22 | 严然 | 一种纳米复合物及应用 |
CN114181286A (zh) * | 2021-11-01 | 2022-03-15 | 清华大学 | 一种纳米蛋白复合物、药物递送***及应用 |
WO2024010353A1 (ko) * | 2022-07-05 | 2024-01-11 | 주식회사 빌릭스 | 페길화된 빌리루빈을 포함하는 염증성 질환의 예방 또는 치료용 약학 조성물 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5010073A (en) * | 1989-10-05 | 1991-04-23 | The Rockefeller University | Use of liposomes as carriers for metalloporphyrins |
US6916488B1 (en) | 1999-11-05 | 2005-07-12 | Biocure, Inc. | Amphiphilic polymeric vesicles |
GB0004549D0 (en) | 2000-02-25 | 2000-04-19 | Isis Innovation | Degradation fragments |
ES2306785T3 (es) | 2001-11-02 | 2008-11-16 | The Governors Of The University Of Alberta | Composiciones de micelas que contienen fosfolipidos pegilados y un fotosensibilizador. |
US9205047B2 (en) * | 2005-04-25 | 2015-12-08 | The Governing Council Of The University Of Toronto | Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix |
US20070032842A1 (en) * | 2005-08-03 | 2007-02-08 | Strong Nathan R | Phototherapy Device for Treating Hyperbilirubinemia |
KR20080095130A (ko) * | 2007-04-23 | 2008-10-28 | 한국과학기술연구원 | pH 민감성 블록공중합체를 이용한 약물전달체 제조 및응용 |
WO2009061406A1 (en) * | 2007-11-05 | 2009-05-14 | The Trustees Of Princeton University | Nanoparticles for photodynamic therapy |
CA2738766A1 (en) * | 2008-09-25 | 2010-04-01 | Invivo Therapeutics Corporation | Spinal cord injury, inflammation, and immune-disease: local controlled release of therapeutic agents |
JP5849947B2 (ja) * | 2010-03-29 | 2016-02-03 | アステラス製薬株式会社 | 放出制御医薬組成物 |
WO2012162557A1 (en) * | 2011-05-24 | 2012-11-29 | Agienic, Inc. | Compositions and methods for antimicrobial metal nanoparticles |
US20130345614A1 (en) | 2012-06-22 | 2013-12-26 | Viraj P. Mane | Device for extracorporeal photo-isomerization for hyperbilirubinemia, and method thereof |
-
2014
- 2014-12-26 ES ES14875349T patent/ES2774035T3/es active Active
- 2014-12-26 WO PCT/KR2014/012912 patent/WO2015099492A1/ko active Application Filing
- 2014-12-26 DK DK14875349.4T patent/DK3088353T3/da active
- 2014-12-26 HU HUE14875349A patent/HUE047912T2/hu unknown
- 2014-12-26 PT PT148753494T patent/PT3088353T/pt unknown
- 2014-12-26 EP EP14875349.4A patent/EP3088353B8/en active Active
- 2014-12-26 US US15/104,040 patent/US11904019B2/en active Active
- 2014-12-26 PL PL14875349T patent/PL3088353T3/pl unknown
- 2014-12-26 KR KR1020140190881A patent/KR101681299B1/ko active IP Right Grant
-
2020
- 2020-02-14 HR HRP20200256TT patent/HRP20200256T1/hr unknown
-
2023
- 2023-10-18 US US18/381,305 patent/US20240082408A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11904019B2 (en) | 2024-02-20 |
KR101681299B1 (ko) | 2016-12-05 |
PL3088353T3 (pl) | 2020-07-13 |
EP3088353B8 (en) | 2020-04-08 |
EP3088353A4 (en) | 2016-12-28 |
EP3088353A1 (en) | 2016-11-02 |
US20170028076A1 (en) | 2017-02-02 |
WO2015099492A1 (ko) | 2015-07-02 |
HRP20200256T1 (hr) | 2020-11-13 |
US20240082408A1 (en) | 2024-03-14 |
DK3088353T3 (da) | 2020-02-24 |
EP3088353B1 (en) | 2019-12-18 |
HUE047912T2 (hu) | 2020-05-28 |
ES2774035T3 (es) | 2020-07-16 |
KR20150079436A (ko) | 2015-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT3088353T (pt) | Partículas de bilirrubina e sua preparação para utilização em terapia | |
HRP20170888T1 (hr) | Spoj tubulisina, metode pripreme i primjena | |
HK1221908A1 (zh) | 多特異 試劑,其製備方法和用途 | |
HK1206025A1 (en) | Thiophene miazines derivate, preparation method therefor, and medical application thereof | |
EP2953012A4 (en) | ELECTRONIC SKIN, METHOD OF MANUFACTURE AND USE THEREOF | |
EP2968304A4 (en) | 4-PHENYLPIPERIDINES, PREPARATION THEREOF AND USE THEREOF | |
EP2968303A4 (en) | OCTAHYDROCYCLOPENTAPYROLE AND THEIR PREPARATION AND USE | |
HK1203317A1 (en) | Edible composition, preparation method and use thereof | |
EP2979724A4 (en) | CATHETER, CATHETERMANULATING ELEMENT AND CATHETER MANUFACTURING METHOD | |
HK1209324A1 (en) | Nanozymes, methods of making nanozymes, and methods of using nanozymes | |
GB201319878D0 (en) | Method, Array and use thereof | |
HK1203398A1 (en) | Edible composition, preparation method and use thereof | |
HK1218120A1 (zh) | 三環苯並氧雜硼化合物、其製備方法與應用 | |
HK1203397A1 (zh) | 可食用組合物及其製備方法和用途 | |
EP2813495A4 (en) | 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE THEREOF | |
EP3065712A4 (en) | Microparticles, methods for their preparation and use | |
HK1221162A1 (zh) | 提取物和含有該提取物的製劑 | |
EP2952519A4 (en) | PROTOPANOXADIOL DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | |
EP2950646A4 (en) | AGROCHEMICAL COMPOSITION, PROCESS FOR PREPARATION AND USE THEREOF | |
ZA201603990B (en) | Taxane compound, and preparation method and use thereof | |
ZA201600015B (en) | Anti-fibrogenic compounds, methods and uses thereof | |
EP2980096A4 (en) | 2,3,5-trihydroxy-androst-6-one, as well as method of preparation and use thereof | |
SI3033532T1 (sl) | Vezni element, uporaba in postopek | |
EP2987794A4 (en) | VINBLASTINE DERIVATIVES, PROCESS FOR THEIR SYNTHESIS AND THEIR APPLICATION | |
ZA201603682B (en) | Taxanes compounds, preparation method therefor, and uses thereof |